生物技术公司Quotient Therapeutics近日宣布与制药巨头默沙东达成一项战略合作，双方将共同运用先进的体细胞基因组学平台技术，针对炎症性肠病领域开展创新药物靶点的探索工作。此次合作标志着两家企业在精准医疗领域的深度联动，有望为炎症性肠病患者带来新的治疗希望。
通过整合Quotient特有的体细胞基因组学平台与默沙东在药物研发方面的丰富经验，合作双方计划系统性地筛选和验证与炎症性肠病发病机制相关的潜在治疗靶点。这一创新合作模式将充分发挥双方在技术平台和临床开发方面的互补优势，加速创新疗法的研发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.